Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice

Epilepsy Research

Volumn 91, Issue 1, 2010, Pages 57-65

  Fischborn, Sarah Verena ^a   Soerensen, Jonna ^a   Potschka, Heidrun ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amygdala kindling; COX 2 inhibitor; EP1 receptor; Prostaglandin E2; Temporal lobe epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 2; MISOPROSTOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 1; SC 51089; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ENZYME INHIBITION; KINDLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEIZURE THRESHOLD; TEMPORAL LOBE EPILEPSY;

AMYGDALA; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HYDRAZINES; KINDLING, NEUROLOGIC; MALE; MICE; OXAZEPINES; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE;

EID: 77956010656     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.06.012     Document Type: Article

References (33)

1. Abe T., Kunz A., Shimamura M., Zhou P., Anrather J., Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J. Cereb. Blood Flow Metab. 2009, 29:66-72.
2. Akarsu E.S., Ozdayi S., Algan E., Ulupinar F. The neuronal excitability time-dependently changes after lipopolysaccharide administration in mice: possible role of cyclooxygenase-2 induction. Epilepsy Res. 2006, 71:181-187.
3. Baik E.J., Kim E.J., Lee S.H., Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999, 843:118-129.
4. Dhir A., Naidu P.S., Kulkarni S.K. Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice. Fundam. Clin. Pharmacol. 2006, 20:255-261.
5. Dhir A., Naidu P.S., Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16:691-697.
6. Holtman L., van Vliet E.A., van Schaik R., Queiroz C.M., Aronica E., Groter J.A. Effect of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 2009, 84(1):56-66. Epub 2009 Jan 30.
7. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S., Orio M., Iadecola C. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 2006, 12:225-229.
8. Kawaguchi K., Hickey R.W., Rose M.E., Zhu L., Chen J., Graham S.H. Cyclooxygenase-2 expression is induced in rat brain after kainate-induced seizures and promotes neuronal death in CA3 hippocampus. Brain Res. 2005, 1050(1-2):130-137.
9. Kim D.K., Jang T.J. Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure. Int. J. Exp. Pathol. 2006, 87:73-78.
10. Kim E.J., Lee J.E., Kwon K.J., Lee S.H., Moon C.H., Baik E.J. Differential roles of cyclooxygenase isoforms after kainic acid-induced prostaglandin E(2) production and neurodegeneration in cortical and hippocampal cell cultures. Brain Res. 2001, 908:1-9.
11. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008, 1193:153-161.
12. Kulkarni S.K., Dhir A. Cyclooxygenase in epilepsy: from perception to application. Drugs Today (Barc.) 2009, 45:135-154.
13. Kunz T., Oliw E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci. 2001, 13(3):569-575.
14. Kunz T., Marklund N., Hillered L., Oliw E.H. Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat. Brain Res. Cogn. Brain Res. 2005, 25:826-832.
15. Laufer S. Osteoarthritis therapy-are there still unmet needs?. Rheumatology (Oxford) 2004, 43(Suppl. 1):i9-i15.
16. Li J., Liang X., Wang Q., Breyer R.M., McCullough L., Andreasson K. Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci. Lett. 2008, 438:210-215.
17. Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002, 50:105-123.
18. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 2004, 24:257-268.
19. McIntyre D.C., Gilby K.L. Kindling as a model of human epilepsy. Can. J. Neurol. Sci. 2009, 36(Suppl. 2):S33-S35.
20. Medeiros F.D.C., Medeiros M.A., Rao V.S., Figueiredo E.G. Effects of misoprostol on pentylenetetrazol-induced seizures in mice. Arq. Neuropsiquiatr. 1997, 55:677-679.
21. Paxinos G., Franklin K. The mouse brain in stereotaxic coordinates 2004, Akademic Press, London.
22. Pekcec A., Unkruer B., Schlichtiger J., Soerensen J., Hartz A.M., Bauer B., van Vliet E.A., Gorter J.A., Potschka H. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 2009, 330:939-947.
23. Potschka H., Friedrichs E., Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br. J. Pharmacol. 2000, 131(2):203-212.
24. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol. Ther. 2010, 125:118-127.
25. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
26. Schlichtiger J., Pekcec A., Bartmann H., Winter P., Fuest C., Soerensen J., Potschka H. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br. J. Pharmacol. 2010, 160(5):1062-1071.
27. Takemiya T., Maehara M., Matsumura K., Yasuda S., Sugiura H., Yamagata K. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci. Res. 2006, 56:103-110.
28. Takemiya T., Matsumura K., Yamagata K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem. Int. 2007, 51:112-120.
29. Takemiya T., Suzuki K., Sugiura H., Yasuda S., Yamagata K., Kawakami Y., Maru E. Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling. Prostaglandins Other Lipid Mediat. 2003, 71:205-216.
30. Toscano C.D., Kingsley P.J., Marnett L.J., Bosetti F. NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology 2008, 29(6):1114-1120. Epub 2008 Sep 11.
31. Tu B., Bazan N.G. Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exp. Neurol. 2003, 179:167-175.
32. van Vliet E.A., Zibell G., Pekcec A., Schlichtiger J., Edelbroek P.M., Holtman L., Aronica E., Gorter J.A., Potschka H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
33. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., Potschka H. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.